Targeting a protein to improve lung cancer treatment
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice
This study is looking at a way to improve lung cancer treatment by focusing on a protein called Tip60, which affects immune cells; researchers hope that by reducing the activity of certain immune cells while keeping others strong, they can help the body fight tumors better and see how this might work with regular treatments like chemotherapy and radiation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10877112 on NIH RePORTER |
What this research studies
This research investigates the potential of targeting Tip60, a protein that plays a crucial role in the function of certain immune cells, to enhance lung cancer treatment. By using specialized mice models, the researchers aim to decrease the suppressive functions of regulatory T cells while preserving the activity of conventional T cells, which could lead to reduced tumor growth. The study will also explore how this targeting affects the response of tumors to standard therapies like chemotherapy and radiation. The approach involves developing and testing new compounds designed to degrade Tip60 specifically in cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with lung cancer who may benefit from enhanced immune responses to their tumors.
Not a fit: Patients with cancers other than lung cancer or those who do not have a suitable immune profile may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective lung cancer treatments by improving immune responses against tumors.
How similar studies have performed: While targeting proteins for cancer treatment is a growing field, this specific approach using Tip60 and PROTAC technology is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Philadelphia, United States
- Children's Hosp of Philadelphia — Philadelphia, United States (Active)
Researchers
- Principal investigator: Hancock, Wayne William — Children's Hosp of Philadelphia
- Study coordinator: Hancock, Wayne William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.